Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 25:631:122526.
doi: 10.1016/j.ijpharm.2022.122526. Epub 2022 Dec 21.

Enhancing tabletability of high-dose tablets by tailoring properties of spray-dried insulin particles

Affiliations

Enhancing tabletability of high-dose tablets by tailoring properties of spray-dried insulin particles

Mahdieh Dagina Pedersen et al. Int J Pharm. .

Abstract

The oral delivery of proteins and peptides provides an attractive dosing option due to its high patient compliance. However, as oral formulations of such macromolecules require the addition of typically poorly compactable permeation enhancers, the compression behaviour in tableting processes can become challenging. In this study, we show that poor compression behaviour can be overcome by tailoring the properties of peptide or protein particles, especially in high-dose tablet formulations. Spray-dried particles with varying particle size and morphology were produced and characterized. The particles were then evaluated for tabletability in well- and poorly tabletable formulations. Tabletability was found to be enhanced most with small and non-hollow spray-dried insulin particles in both formulations. The enhancement was more pronounced in the poorly tabletable formulation than in the well-tabletable one. Thus, the API particle properties play a key role, when evaluating manufacturability of poorly tabletable formulations.

Keywords: High-dose formulations; Insulin; MCC (CAS: 9004-34-6); Magnesium stearate (CAS: 557-04-0); Maltitol (CAS: 585-88-6); Oral drug delivery; Oral peptide formulations; Oral protein formulations; Sorbitol (CAS: 50-70-4); Spray-dried particles; Starch (CAS: 9005-25-8); Tablet manufacturing; Tabletability.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.